Tigecycline in the Treatment of Ventilator-Associated Pneumonia Due to Stenotrophomonas maltophilia: A Multicenter Retrospective Cohort Study.

Lei ZhaDayan ZhangLingling PanZhichu RenXiang LiYi ZouShirong LiShuangqi LuoGang YangBoris Tefsen

Published in: Infectious diseases and therapy (2021)

The standard dose of tigecycline therapy was associated with a lower clinical and microbiological cure rate but not associated with an increased 28-day mortality in patients with S. maltophilia VAP compared with fluoroquinolones. Considering the unfavorable clinical outcomes, we therefore recommend against using the standard dose of tigecycline in treating S. maltophilia VAP unless new clinical evidence emerges.

Keyphrases

acinetobacter baumannii
klebsiella pneumoniae
multidrug resistant
intensive care unit
stem cells
mesenchymal stem cells
cystic fibrosis
acute respiratory distress syndrome
cell therapy
replacement therapy
community acquired pneumonia